Testing malaria medicines in uncomplicated falciparum malaria
Part of Infections clinical trials.
This trial studies how well and how safely different anti-malaria medicines work for people who have uncomplicated malaria caused by Plasmodium falciparum. You may be eligible if you have a confirmed infection with a certain parasite level and do not have signs of severe disease or major health conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age must match the study group: 18+ for one part, 12–17 for another, and 2–11 for another
- You must have confirmed “uncomplicated” falciparum malaria only (no other malaria type) with a specific parasite level in your blood
- You must meet weight limits that vary by study part (adults typically about 35–90 kg; children part needs at least 10 kg)
- You must have fever now or within the last 24 hours (temperature thresholds are specified)
- You must not have severe/complicated malaria, mixed malaria infections, or clinically significant anemia/low hemoglobin
- You must not be pregnant or breastfeeding, and must be able/willing to use effective birth control if applicable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a combination of three medicines to treat uncomplicated malaria, to see if it works as well and is as well tolerated as a two-medicine combination. You may join if you have a specific type of malaria infection in a mild form and meet safety requirements.
This study tests a new experimental antimalarial drug (GSK3772701) to see if it can safely and effectively treat uncomplicated malaria caused by P. falciparum parasites. You would receive the study drug by mouth and be monitored closely with blood tests and heart rhythm checks.
This is an early-stage safety study testing a new experimental drug (GSK4425689A) in healthy volunteers. Researchers want to find safe doses and understand how the body processes this medication.
This Phase 1 study tests how safe a combination oral medicine (ZY19489 with ferroquine) is in adults who carry malaria in their blood but have no symptoms. It also studies how the body absorbs and processes the medicines.
This trial tests whether adding a cancer drug called imatinib to standard malaria treatment works better and is safe. Researchers will enroll adults and children with uncomplicated malaria caused by P. falciparum parasites and monitor them in the hospital for 2–3 days.
This study gives healthy volunteers a controlled infection with a type of malaria (vivax) to see how the infection behaves and how well curative anti-malaria medicine works. It may help researchers better design and test future malaria vaccines and treatments.
Hear when a new Uncomplicated Plasmodium Falciparum Malaria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.